72 research outputs found

    Uncertainties in Atmospheric Muon-Neutrino Fluxes Arising from Cosmic-Ray Primaries

    Full text link
    We present an updated calculation of the uncertainties on the atmospheric muon-neutrino flux arising from cosmic-ray primaries. For the first time, we include recent measurements of the cosmic-ray primaries collected since 2005. We apply a statistical technique that allows the determination of correlations between the parameters of the GSHL primary-flux parametrisation and the incorporation of these correlations into the uncertainty on the muon-neutrino flux. We obtain an uncertainty related to the primary cosmic rays of around (5–15)%(5\text{--}15)\%, depending on energy, which is about a factor of two smaller than the previously determined uncertainty. The hadron production uncertainty is added in quadrature to obtain the total uncertainty on the neutrino flux, which is reduced by ≈5%\approx 5\%. To take into account an unexpected hardening of the spectrum of primaries above energies of 100100 GeV\text{GeV} observed in recent measurements, we propose an alternative parametrisation and discuss its impact on the neutrino flux uncertainties

    Search for heavy neutral leptons decaying into muon-pion pairs in the MicroBooNE detector

    Get PDF
    This document was prepared by the MicroBooNE Collaboration using the resources of the Fermi National Accelerator Laboratory (Fermilab), a U.S. Department of Energy, Office of Science, HEP User Facility. Fermilab is managed by Fermi Research Alliance, LLC (FRA), acting under Contract No. DE-AC02-07CH11359. MicroBooNE is supported by the following: the U.S. Department of Energy, Office of Science, Offices of High Energy Physics and Nuclear Physics; the U.S. National Science Foundation; the Swiss National Science Foundation; the Science and Technology Facilities Council (STFC), part of the United Kingdom Research and Innovation; and The Royal Society (United Kingdom). Additional support for the laser calibration system and cosmic ray tagger was provided by the Albert Einstein Center for Fundamental Physics, Bern, Switzerland.We present upper limits on the production of heavy neutral leptons (HNLs) decaying to Όπ pairs using data collected with the MicroBooNE liquid-argon time projection chamber (TPC) operating at Fermilab. This search is the first of its kind performed in a liquid-argon TPC. We use data collected in 2017 and 2018 corresponding to an exposure of 2.0×1020 protons on target from the Fermilab Booster Neutrino Beam, which produces mainly muon neutrinos with an average energy of ≈800  MeV. HNLs with higher mass are expected to have a longer time of flight to the liquid-argon TPC than Standard Model neutrinos. The data are therefore recorded with a dedicated trigger configured to detect HNL decays that occur after the neutrino spill reaches the detector. We set upper limits at the 90% confidence level on the element |UÎŒ4|2 of the extended PMNS mixing matrix in the range |UÎŒ4|2<(6.6–0.9)×10−7 for Dirac HNLs and |UÎŒ4|2<(4.7–0.7)×10−7 for Majorana HNLs, assuming HNL masses between 260 and 385 MeV and |Ue4|2=|Uτ4|2=0.Fermilab is managed by Fermi Research Alliance, LLC (FRA), acting under Contract No. DE-AC02-07CH1135

    Energy Estimation of Cosmic Rays with the Engineering Radio Array of the Pierre Auger Observatory

    Full text link
    The Auger Engineering Radio Array (AERA) is part of the Pierre Auger Observatory and is used to detect the radio emission of cosmic-ray air showers. These observations are compared to the data of the surface detector stations of the Observatory, which provide well-calibrated information on the cosmic-ray energies and arrival directions. The response of the radio stations in the 30 to 80 MHz regime has been thoroughly calibrated to enable the reconstruction of the incoming electric field. For the latter, the energy deposit per area is determined from the radio pulses at each observer position and is interpolated using a two-dimensional function that takes into account signal asymmetries due to interference between the geomagnetic and charge-excess emission components. The spatial integral over the signal distribution gives a direct measurement of the energy transferred from the primary cosmic ray into radio emission in the AERA frequency range. We measure 15.8 MeV of radiation energy for a 1 EeV air shower arriving perpendicularly to the geomagnetic field. This radiation energy -- corrected for geometrical effects -- is used as a cosmic-ray energy estimator. Performing an absolute energy calibration against the surface-detector information, we observe that this radio-energy estimator scales quadratically with the cosmic-ray energy as expected for coherent emission. We find an energy resolution of the radio reconstruction of 22% for the data set and 17% for a high-quality subset containing only events with at least five radio stations with signal.Comment: Replaced with published version. Added journal reference and DO

    Measurement of the Radiation Energy in the Radio Signal of Extensive Air Showers as a Universal Estimator of Cosmic-Ray Energy

    Full text link
    We measure the energy emitted by extensive air showers in the form of radio emission in the frequency range from 30 to 80 MHz. Exploiting the accurate energy scale of the Pierre Auger Observatory, we obtain a radiation energy of 15.8 \pm 0.7 (stat) \pm 6.7 (sys) MeV for cosmic rays with an energy of 1 EeV arriving perpendicularly to a geomagnetic field of 0.24 G, scaling quadratically with the cosmic-ray energy. A comparison with predictions from state-of-the-art first-principle calculations shows agreement with our measurement. The radiation energy provides direct access to the calorimetric energy in the electromagnetic cascade of extensive air showers. Comparison with our result thus allows the direct calibration of any cosmic-ray radio detector against the well-established energy scale of the Pierre Auger Observatory.Comment: Replaced with published version. Added journal reference and DOI. Supplemental material in the ancillary file

    Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

    Get PDF
    OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

    Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

    Get PDF
    The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

    Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

    Get PDF
    BACKGROUND: The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. METHODS: In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, we enrolled 12,092 patients who had at least one of the following conditions: an acute coronary syndrome within the previous 30 to 365 days, cerebrovascular atherosclerotic disease, peripheral vascular arterial disease, or diabetes mellitus with coronary artery disease. Patients were randomly assigned to receive either evacetrapib at a dose of 130 mg or matching placebo, administered daily, in addition to standard medical therapy. The primary efficacy end point was the first occurrence of any component of the composite of death from cardiovascular causes, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina. RESULTS: At 3 months, a 31.1% decrease in the mean LDL cholesterol level was observed with evacetrapib versus a 6.0% increase with placebo, and a 133.2% increase in the mean HDL cholesterol level was seen with evacetrapib versus a 1.6% increase with placebo. After 1363 of the planned 1670 primary end-point events had occurred, the data and safety monitoring board recommended that the trial be terminated early because of a lack of efficacy. After a median of 26 months of evacetrapib or placebo, a primary end-point event occurred in 12.9% of the patients in the evacetrapib group and in 12.8% of those in the placebo group (hazard ratio, 1.01; 95% confidence interval, 0.91 to 1.11; P=0.91). CONCLUSIONS: Although the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease. (Funded by Eli Lilly; ACCELERATE ClinicalTrials.gov number, NCT01687998 .)

    Predicting Transport Effects of Scintillation Light Signals in Large-Scale Liquid Argon Detectors

    No full text
    Liquid argon is being employed as a detector medium in neutrino physics and Dark Matter searches. A recent push to expand the applications of scintillation light in Liquid Argon Time Projection Chamber neutrino detectors has necessitated the development of advanced methods of simulating this light. The presently available methods tend to be prohibitively slow or imprecise due to the combination of detector size and the amount of energy deposited by neutrino beam interactions. In this work we present a semi-analytical model to predict the quantity of argon scintillation light observed by a light detector with a precision better than 10%10\%, based only on the relative positions between the scintillation and light detector. We also provide a method to predict the distribution of arrival times of these photons accounting for propagation effects. Additionally, we present an equivalent model to predict the number of photons and their arrival times in the case of a wavelength-shifting, highly-reflective layer being present on the detector cathode. Our proposed method can be used to simulate light propagation in large-scale liquid argon detectors such as DUNE or SBND, and could also be applied to other detector mediums such as liquid xenon or xenon-doped liquid argon